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Variations in intracellular levels of p53 regulate many cellular functions and determine tumor susceptibility.
Major mechanisms modulating p53 levels include phosphorylation and interaction of p53 with specific ubiq-
uitin ligases that promote its degradation. N-terminal phosphorylation regulates the interaction of p53 with
several regulatory molecules. Vaccinia-related kinase 1 (VRK1) is the prototype of a new Ser-Thr kinase family
in the human kinome. VRK1 is located in the nucleus outside the nucleolus. Overexpression of VRK1 increases
the stability of p53 by a posttranslational mechanism leading to its accumulation by a mechanism independent
of the Chk2 kinase. Catalytically inactive VRK1 protein (a K179E mutant) does not induce p53 accumulation.
VRK1 phosphorylates human p53 in Thr18 and disrupts p53-Mdm2 interaction in vitro, although a significant
decrease in p53 ubiquitination by Mdm2 in vivo was not detected. VRK1 kinase does not phosphorylate Mdm2.
VRK1-mediated p53 stabilization was also detected in Mdm2/ cells. VRK1 also has an additive effect with
MdmX or p300 to stabilize p53, and p300 coactivation and acetylation of p53 is enhanced by VRK1. The p53
stabilized by VRK1 is transcriptionally active. Suppression of VRK1 expression by specific small interfering
RNA provokes several defects in proliferation, situating the protein in the regulation of this process. VRK1
might function as a switch controlling the proteins that interact with p53 and thus modifying its stability and
activity. We propose VRK1 as the first step in a new pathway regulating p53 activity during cell proliferation.
Regulation of p53 levels plays a major role in determining
the fate of a cell and its susceptibility to tumor development
(17, 19). The p53 protein is at a crossroad in the pathways
implicated in the cellular response to many different types of
stresses, such as genotoxic damage by UV or ionizing irradia-
tion, hypoxia, and heat shock (36), and it has been implicated
in different cell cycle checkpoints (7, 48). Several cell protec-
tion mechanisms are based on the ability of the p53 protein to
regulate the progression of the cell cycle, the induction of
apoptosis, or replicative senescence (6, 46, 50). These re-
sponses are controlled by the p53 protein level. p53 is a short-
lived protein that is maintained at low levels in the cell under
normal conditions and increases in response to stress. The
levels and stability of the p53 protein in the cell are mainly
controlled by its interactions with the negative regulator Mdm2
(hdm2 in humans) (3) or with other E3 ubiquitin ligases, such
as COP1 (14) or Pirh2 (24). Mdm2 targets p53 for degradation
by the ubiquitination pathway, promotes its nuclear export,
and thus allows cell cycle progression (3). The new ubiquitin
ligases COP1 and Pirh2 are also negative regulators of p53
function, targeting p53 for degradation by the proteasome in a
ubiquitin-dependent fashion, and like Mdm2 are encoded by
p53-inducible genes (14, 24). Interactions with stabilizing pro-
teins, such as p300 (53), MdmX (29, 47), or the deubiquitinase
HAUSP (25), also play a major role in p53 stabilization and
activation.
Phosphorylation of p53 in its transactivation domain in the
N-terminal region is one of the mechanisms by which the
interaction of p53 with Mdm2 and its transcriptional activity
are regulated (37). Several kinases are able to phosphorylate
the p53 molecule in its N terminus; each of them is implicated
in the response to different types of stress stimulation (31).
These phosphorylations have a partial overlap in their effects
on either activation of p53 transcriptional activity (15) and
coactivator binding (11) or p53 interaction with Mdm2. After
stimulation, there is an increase in p53 coactivator response
that is followed several hours later by an increase in downregu-
latory proteins, such as Mdm2.
Thr18 residue phosphorylation, in the transactivation do-
main of p53, has been implicated in both disruption of p53-
Mdm2 interaction and p300 coactivator recruitment, which
acetylates the p53 carboxy terminus. This leads to a decrease in
p53 degradation and its subsequent stabilization and to an
increase in p53-dependent transactivation activity. The p53
activity is also regulated by phosphorylation in its carboxy
terminus mediated by several known kinases, such as protein
kinase C (35) or casein kinase II, that can modulate its oli-
gomerization status (40, 41) and stabilize p53-DNA interac-
tion.
In the human kinome, the new VRK (vaccinia-related ki-
nase) family of serine-threonine kinases, composed of three
members, is an early divergent branch related to casein kinases
(30). The conservation of the kinase domain is weak, but in the
cases of VRK1 and VRK2, it is catalytically active (5, 27, 44,
45). Originally, these proteins were identified by their homol-
ogy to the catalytic domain of the B1R vaccinia virus kinase
(34). B1R is an early protein essential for viral replication (4,
26). The VRK family has only one member in Drosophila
melanogaster, locus 97D3, and one member in Caenorhabditis
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elegans, gene F28B12.3 on chromosome 2. Knockout of the
F28B12.3 gene in C. elegans embryos has lethal effects, which
are variable, ranging from arrest at many stages of embryogen-
esis to arrest soon after hatching, and growth is slow (22). In
yeast, there are early precursors of the VRK family. In Schizo-
saccharomyces pombe, the HHP1 gene is involved in DNA
repair in response to gamma irradiation (10); this gene is an
ortholog of the HRR25 gene from Saccharomyces cerevisiae.
For this reason, it was initially postulated to have possible roles
in cell growth regulation and proliferation. VRK1 appears to
be expressed ubiquitously, at very different levels, in many
tissues (34), and in murine embryos it is implicated in the early
phases of hematopoietic development (49). VRK1 in vitro can
phosphorylate human p53 in Thr18 (5, 27), a residue that is
essential for the interaction between p53 and Mdm2 (21, 43).
It also appears to have different expression patterns in specific
tumor types (unpublished data).
In this report, we show that VRK1 is a nuclear kinase that
stabilizes the intracellular protein levels of p53 by a posttrans-
lational mechanism, and thus, it affects p53-dependent tran-
scription. This VRK1 effect is not only dependent on a direct
disruption of the MDM2-p53 interaction, although its overex-
pression increases endogenous p53 Thr18 phosphorylation.
VRK1 also increases p53 carboxy-terminal acetylation directed
by p300 and p53-p300 interaction, an effect that might be
directed by p53 Thr18 phosphorylation and other interactions.
We also show that cells transfected with specific small inter-
fering RNA (siRNA) that suppresses the expression of VRK1
have different defects in cell proliferation, and we propose a
model for VRK1 action on p53.
MATERIALS AND METHODS
Reagents, plasmids, and antibodies. The plasmids containing human p53
wild-type cDNA were obtained from K. Vousden (National Cancer Institute,
Frederick, Md.) or J. Pietenpol (Vanderbilt University, Nashville, Tenn.). The
human cDNA for VRK1 or the K179E mutant was subcloned in plasmid
pcDNA3.1 with the Myc epitope (pcDNA-VRK1myc clone) or in pCEFL-KZ
with the hemagglutinin (HA) epitope (pHA-VRK1 clone). The p53-cis reporter
system (p53-luc) with the luciferase gene was from Stratagene (La Jolla, Calif.).
As a control for transfection, we used the pRenilla-tk (pRL-tk) reporter plasmid
from Promega (Madison, Wis.). Also, the reporter constructs p21-luc, Bax-luc,
and p14-3-3-Luc, containing the promoter of the p53-responsive genes linked to
luciferase (from M. Oren, Rehovot, Israel), were used. The ubiquitin tagged with
the His epitope (clone BRR12-his-Ubiquitin) was from S. Lain and D. Lane
(University of Dundee, Dundee, Scotland). Plasmid pCDNA-Chk2-Myc was
from J. Bartek (Danish Cancer Institute, Copenhagen, Denmark). Plasmids
pCMV-FLAG-Chk2 and pCMV-FLAG-Chk2A347 were from T. Halozanetis
(University of Pennsylvania, Philadelphia). Plasmid pCOC-Mdm2-X2, coding for
the Mdm2 protein, was from Karen Vousden (Beatson Institute, Glasgow, Scot-
land). Plasmid p3.1MdmXNIF, encoding full-length MdmX, was from S. Ber-
berich (Wright State University, Dayton, Ohio). Plasmid pCMV-p300-CHA
was from Richard Eckner (University of Zurich, Zurich, Switzerland). All plas-
mids used for transfection were endotoxin free and purified with the JetStar Maxi
kit from Genomed (Bad Oeynhausen, Germany).
The anti--actin antibody was from Sigma (St. Louis, Mo.). A polyclonal
antibody against the Myc epitope was from Upstate Biotechnology (Lake Placid,
N.Y.), and the mouse monoclonal antibody HA probe (F7) against the HA tag
was from Santa Cruz (Santa Cruz, Calif.). The monoclonal antibody FTP18
against p53 phosphorylated in Thr18 was a gift of T. Hupp (University of
Dundee) (9). The p53 protein was detected with a mix of DO1 antibody (Santa
Cruz) and Pab1801 (Santa Cruz) used at 1:500 and 1:1,000, respectively. To
detect endogenous p53 Thr18 and Ser15 phosphorylation in vivo, specific rabbit
polyclonal antibodies from Santa Cruz were used. A goat anti-mouse–horserad-
ish peroxidase and a goat anti-rabbit–horseradish peroxidase (Amersham Phar-
macia Biotech) were used at 1:5,000 in Western blotting. VRK1 was detected by
using a rabbit polyclonal antibody against the glutathione S-transferase (GST)-
VRK1 fusion protein. The immunoblots were developed by chemiluminescence
using ECL reagent (Amersham Biosciences). A rabbit antiserum from Upstate
Biotechnology detecting specifically acetylated p53 in Lys373 and Lys382 was
used. 4B2 monoclonal antibody (a gift of Sonia Lain) was used for the detection
of the Mdm2 protein.
Fusion proteins. The human GST-VRK1 fusion protein has the full-length
VRK1 and was described previously (27). The GST-p53 fusion protein FP221
containing the N terminus of murine p53 (residues 1 to 85) (32) was a gift of D.
Meek (University of Dundee). A Thr18Ala substitution was introduced using the
Quick-Change mutagenesis system from Stratagene (San Diego, Calif.). The
GST-Mdm2 protein encoding amino acids 1 to 188 was from A. Levine. p53-GST
constructs including the fragments 90 to 290 and 290 to 390 were from T.
Kouzarides (Cancer Research UK Institute, Cambridge, United Kingdom). The
GST fusion proteins were purified using glutathione-Sepharose resin (Amer-
sham Biosciences, Little Chalfont, United Kingdom) and eluted from the beads
with glutathione according to the manufacturer’s instructions. Proteins were
quantified using a Bradford protein assay kit (Bio-Rad, Hercules, Calif.). To
generate an inactive VRK1 kinase, a K179E substitution was introduced using
the Quick-Change mutagenesis system in both the GST-VRK1 and eukaryotic
expression constructs. The mutant constructs were confirmed by DNA sequenc-
ing.
VRK1 protein kinase assay. The kinase assay was performed in a 25-l final
volume containing 1 or 2 g of VRK1 protein or VRK1-K179E mutant and 2 g
of protein substrates as appropriate. It was performed in kinase buffer (50 mM
Tris-HCl, pH 7.5, 100 M ATP, 50 mM MgCl2, 1 mM dithiothreitol [DTT]) and
5 Ci of [-32P]ATP. The reaction mixture was incubated for 30 min at 30°C. The
phosphorylated proteins were analyzed by electrophoresis in a 0.1% sodium
dodecyl sulfate (SDS)–10% polyacrylamide gel. After the gel was stained with
Coomassie blue (Merck), the radioactivity incorporated was analyzed using a
Bio-Rad FX molecular imager system. Quantification was performed with the
program Image Quant (Bio-Rad). In all cases, the analysis was performed within
the linear response region of the system.
Binding of Mdm2 to GST-p53 fusion proteins. To determine the abilities of
phosphorylated and nonphosphorylated p53 to bind to Mdm2 in vitro, GST
pull-down assays were performed using in vitro-translated proteins. For these
experiments, glutathione S-transferase–p53 fusion proteins were first phosphor-
ylated by VRK1 using 2 g of VRK1-His6 recombinant protein and 1 to 2 g of
GST-p53 as a substrate. The reaction was carried out in kinase buffer (50 mM
Tris-HCl, pH 7.5, 50 M MgCl2, 1 mM DTT) at 30°C for 3 h with 0.5 mM
Mg-ATP. Following phosphorylation, the GST-p53 proteins were adsorbed onto
glutathione-Sepharose 4B beads (Amersham Biosciences), and the beads were
washed. Mdm2 protein was translated in the presence of [35S]methionine using
a reticulocyte lysate in vitro transcription-translation kit (Promega) according to
the manufacturer’s instructions. The GST-p53 proteins were incubated at 4°C
with 35S-labeled Mdm2 in 200 l of the binding-washing buffer (50 mM Tris, pH
7.4, 250 mM NaCl, 0.1% Triton X-100, 5 mM EDTA, 2 mM DTT) for 2 h. The
complexes were washed with washing buffer, boiled in sample buffer, and ana-
lyzed by SDS-polyacrylamide gel electrophoresis. The gels were dried and ex-
posed to X-ray films or analyzed with a Bio-Rad phosphorimager.
Cell lines, transfections, and immunoprecipitation. The human lung cancer
cell lines A549 (p53/) and H1299 (p53/) were grown in RPMI supple-
mented with 10% fetal calf serum, glutamine, penicillin, and streptomycin in a
humidified 5% CO2 atmosphere. The HCT116 wild-type p53 cell line was grown
in McCoy’s 5A supplemented medium. For transfection experiments, H1299
cells were plated in 60- or 100-mm-diameter dishes and transfected with the
plasmid indicated in the specific experiments, either by the calcium phosphate
precipitation method or with JetPI reagent (Polytransfection, Illkirch, France).
The cells were lysed 36 h postransfection in lysis buffer (50 mM Tris-HCl, pH 8,
150 mM NaCl, 5 mM EDTA, and 1% Triton X-100, plus protease and phos-
phatase inhibitors) or acetylation immunoprecipitation lysis buffer (50 mM
HEPES, pH 7.8, 200 mM NaCl, 1% [vol/vol] Triton X-100, 10 mM EDTA, 5 mM
DTT, 5 M trichostatin A, and protease and phosphatase inhibitors), and 40 g
of whole-cell extract was processed for SDS-polyacrylamide gel electrophoresis
and subjected to immunoblotting with the appropriate antibodies. A549 cells
were transfected with Lipofectamine 2000 reagent (Invitrogen) in 60-mm-diam-
eter dishes. The immortalized fibroblasts from double-knockout p53/Mdm2 mice
(33), a gift of G. Lozano (M. D. Anderson Cancer Center, Houston, Tex.), were
grown in Dulbecco’s modified Eagle’s medium with 10% fetal calf serum and
antibiotics. When indicated, cycloheximide (Sigma) was added to a final concen-
tration of 50 g/ml, and adriamycin (Sigma) was added to a final concentration
of 0.2 g/ml. The proteasome inhibitor MG132 (Calbiochem) was used at 40 M
for 6 h.
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Where indicated, immunoprecipitation of p53 was performed using either a
mix of the anti-p53 monoclonal antibodies DO-1 and Pab240 (1 g each) or the
polyclonal anti-p53 antibody CM1 (Novocastra, Newcastle, United Kingdom)
and GammaBind G Sepharose (Amersham Biosciences). To immunoprecipitate
p300 protein, a mixture of the rabbit polyclonal antibodies p300-1 and p300-2,
kindly provided by A. Zantema (Leiden University, Leiden, The Netherlands),
was used.
Immunofluorescence and confocal microscopy. H1299 cells (5  105) were
plated on 10-cm2 dishes containing 1-cm-diameter sterile glass coverslips and
transiently transfected as described above; 36 h postransfection, the slides were
transferred to a tissue culture test plate. The cells were washed three times with
phosphate-buffered saline (PBS) and then fixed in 4% paraformaldehyde in PBS
for 30 min at room temperature. After fixation, the cells were permeabilized in
cold PBS containing 0.2% Triton X-100 for 30 min and then treated with 10 mM
glycine for 10 min at room temperature. The cells were blocked with a solution
containing 1% bovine serum albumin in PBS at room temperature for 30 min
and then incubated for 30 min at 37°C or for 1 h at room temperature with a
mixture of anti-p53 antibodies DO-1 and Pab1801 or anti-Myc antibody in
blocking solution. The cells were washed three times with PBS–0.1% Triton
X-100 and incubated with a goat anti-mouse Cy2-labeled antibody (Amersham
Biosciences) or a goat anti-rabbit Cy3-labeled antibody (Amersham Biosciences)
in blocking solution. The cells were washed three times with PBS–0.1% Triton
X-100 and stained with DAPI (4,6-diamidino-2-phenylindol) (1:1,000; Sigma)
in PBS for 10 min at room temperature. The cells were washed with PBS, and
slides were mounted with Gelvatol (Monsanto). Subcellular localization was
analyzed with a Zeiss LSM 510 confocal microscope. For detection of the en-
dogenous VRK1 protein, A549 or HCT116 cells were treated as described above,
but VC1 polyclonal anti-human VRK1 antibody and goat anti-rabbit Cy3-labeled
antibody (Amersham Pharmacia Biotech) were used for detection.
Luciferase assays. Transcription activity was determined using different re-
porter constructs with the luciferase gene. H1299 or A549 cells were seeded at 5
 105 in six-well plates. Twenty-four hours later, the cells were transfected using
the JetPI reagent as directed by the manufacturer or with Lipofectamine 2000
reagent, with the indicated construct in each case including the specific reporter
vector. As an internal control, the pRL-tk plasmid was used for normalization.
Luciferase assays were performed 20 to 36 h after transfection using a dual
luciferase reporter kit (Promega). Luminescence was determined with a Mini-
Lumat LB9506 luminometer (Berthold, Bad Wildbad, Germany).
Immune complex kinase assay. Cells were washed twice with ice-cold PBS,
harvested with a rubber policeman, and centrifuged at 4°C. Cell pellets were
resuspended in ice-cold lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 1.5
mM MgCl2, 10 mM NaF, 10% glycerol, 4 mM EDTA, 1% Triton X-100, 0.1%
SDS) and protease inhibitors, incubated on ice for 30 min, and precleared by
centrifugation at 16,000 g for 20 min at 4°C. Extracts were immunoprecipitated
with an anti-Myc rabbit polyclonal antibody. Immune complexes were recovered
with GammaBind G Sepharose. The beads were sequentially washed with lysis
buffer, 100 mM Tris-HCl at pH 7.5, and kinase buffer. The phosphorylation
reaction was performed as described above.
RT-PCR. H1299 cells were cotransfected as described above and washed in
ice-cold PBS. Total RNA was extracted using the RNAeasy extraction kit from
QIAGEN (Hilden, Germany). The RNA was analyzed and quantified using a
Bioanalyzer 2100 nano-lab chip from Agilent Technologies (Waldbronn, Ger-
many). Total RNA (100 ng) was used in a one-step reverse transcription (RT)
real-time PCR amplification reaction using the Quantitec SYBR Green RT-PCR
kit from QIAGEN in an iCycler (Bio-Rad). The reaction product was analyzed
with iCycler software (Bio-Rad), and the PCR products were resolved in a 1.5%
agarose ethidium bromide gel. The primers used for p53 amplification detection
were 5-CCCCAGCCAAAGAGAAACC-3 and 5-TCCAAGGCCTCATTCA
GCTCT-3, and those for GAPDH (glyceraldehyde-3-phosphate dehydroge-
nase) amplification detection were 5-GGTCTTACTCCTTGGAGGCCATG
T-3 and 5-ACCTAACTACATGGTTTACATGTT-3.
RNA interference experiments. Synthetic selected SMART siRNA duplexes
were purchased from Dharmacon RNA Technologies (Lafayette, Colo.). The
targeted sequences for VRK1 (accession number NM_003384) were GAAAGA
GAGTCCAGAAGTA (duplex siVRK1-1), CAAGGAACCTGGTGTTGAA
(duplex siVRK1-2), GGAATGGAAAGTAGGATTA (duplex siVRK1-3), and
CAAATCTTCTTCTGAACTA (duplex siVRK1-4). A functional siCONTROL
nontargeting siRNA pool from Dharmacon was used as a negative control, and
fluorescently labeled siGLO Lamin A/C siRNA was used for silencing and
transfection efficiency. Transfections of siRNA duplexes at 100 to 200 nM final
concentrations were carried out using Lipofectamine 2000 reagent (Invitrogen)
in HCT116 cells following the manufacturer’s instructions. After transfection,
the cells were processed for Western blotting, immunofluorescence assay, or
video microscopy as indicated. Cell proliferation was measured in 96-well plates
using a Cell Proliferation Kit II (XTT) (Roche).
RESULTS
Endogenous VRK1 is a nuclear protein excluded from the
nucleolus. The intracellular location of the human endogenous
VRK1 protein in the lung carcinoma A549 (p53/p53) cell
line was determined by immunofluorescence and confocal mi-
croscopy studies. For this aim, a specific polyclonal antibody
against the carboxy terminus of human VRK1 was prepared,
and its specificity was confirmed by blocking the antibody sig-
nal when a VRK1-His protein was included in the incubation
(not shown). Analysis of A549 cells by immunofluorescence
located the endogenous VRK1 mainly in the nucleus, colocal-
izing with DAPI staining (Fig. 1A). The analysis of cells in
interphase by confocal microscopy revealed that the endoge-
nous VRK1 protein was mainly distributed in the nucleus and
excluded from the nucleolus, with some present in the perinu-
clear area (Fig. 1B). The same location was demonstrated in
the H1299 cell line (not shown). The levels of endogenous
VRK1 and p53 in the A549 and H1299 cell lines used in this
work were determined by Western blotting (Fig. 1C). A549 has
a wild-type p53 gene, as in normal cells, and the H1299 cell line
has no expression of p53. The two proteins are present in the
same subcellular compartment, but they do not form a stable
complex that can be immunoprecipitated, as would be ex-
pected from a kinase with a casein kinase I type of enzymatic
activity. VRK1 protein, monitored by flow cytometry and by
Western blotting, was detected at similarly high levels through-
out the cell cycle in the different tumor cell lines used (data not
shown).
p53 is stabilized by VRK1 overexpression. Because VRK1
can phosphorylate p53 in vitro in Thr18 (27), it was decided to
study its effects on the levels of p53, which can also be stabi-
lized in the absence of Ser15 or Ser20 phosphorylation (2, 21a).
To test this in vivo, the effect of transfected VRK1 on p53
levels was studied by immunoblot analysis, which reflects the
overall cell population. H1299 (p53/) cells were transfected
with plasmids expressing both VRK1 (pcDNA-VRK1myc) and
human p53 (pCB6p53). An increase in the steady-state levels
of p53 protein induced by VRK1 was detected by Western blot
analysis (Fig. 2A, top). The stabilized p53 protein is extensively
phosphorylated in Thr18 (Fig. 2A, bottom left). The activity of
tagged VRK1 expressed in cultured cells was confirmed in an
in vitro kinase assay with the immunoprecipitated protein (Fig.
2A, bottom right).
To further demonstrate that the stabilization of p53 requires
an active VRK1, a point substitution in the lysine residue
essential for phosphotransfer reactions, K179E, was intro-
duced in the catalytic kinase domain of VRK1, both in GST-
VRK1 and in a mammalian expression construct. The VRK1
protein with the K179E substitution lacks both autophosphor-
ylation and kinase activity on p53 (Fig. 2B, top). The lack of
activity was also confirmed with other substrates (not shown).
Therefore, to study the effect in vivo, H1299 cells were trans-
fected with the inactive mutant, VRK1-K179E. Increasing
amounts of the inactive kinase do not lead to a significant
accumulation of p53 (Fig. 2B, bottom), so we concluded that
the effect is dependent on VRK1 kinase activity.
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To demonstrate that the accumulation is dependent on
VRK1 activity, a dose-response experiment was performed
with H1299 cells. The cells were transfected with a fixed
amount of p53 (1 g of pCB6p53) and various amounts of
VRK1 (0, 3, 5, and 8 g of pcDNA-VRK1myc). The accu-
mulation of p53 is dependent on the amount of transfected
VRK1 (Fig. 2C, top). Other kinases, such as Chk2, have
been shown to stabilize p53 (28) and phosphorylate the
Thr18 residue in response to DNA damage, and an allosteric
effect of these molecules has been identified (8). Therefore,
a similar stabilization experiment using the construct
pCDNA-Chk2-myc instead of VRK1 was performed. The
human Chk2 protein does not stabilize p53 by itself in the
presence of the endogenous VRK1 protein (Fig. 2C, bot-
tom). To confirm that VRK1 does not phosphorylate and
activates Chk2, as is the case with ATM (18, 52), inducing an
indirect Thr18 phosphorylation, an in vitro kinase assay was
performed with a GST-Chk2 kinase-dead mutant protein as
a substrate. There was no phosphorylation of Chk2, but
VRK1 was autophosphorylated as expected (Fig. 2D, top).
Also, an in vivo experiment was performed with H1299 cells
cotransfected with VRK1 and an active (Chk2) or inactive
(Chk2-A347) construct. The stabilization of p53 induced by
VRK1 is independent of the activity of Chk2 (Fg. 2D, bot-
FIG. 1. Localization of the endogenous human VRK1 protein in human A549 lung cancer cells determined by immunofluorescence (A) and
confocal microscopy in interphase (B). The VRK1 protein was detected with the VC1 polyclonal antibody specific for the human protein labeled
with Cy3. The nuclei were detected with DAPI staining, and the cells were identified by phase-contrast microscopy. The overlaps of the VRK1 and
DAPI signals are shown in the merge panels. The bars represent 30 (A) or 10 (B) m. (C) Immunoblot to detect endogenous levels of VRK1 and
p53 in the two carcinoma cell lines used in the study using a polyclonal antibody specific for human VRK1 or anti-p53 monoclonal antibody.
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 o
n
 D
ecem
ber 10, 2012 by Red de Bibliotecas del CSIC
http://m
cb.asm
.org/
D
ow
nloaded from
 
tom) and is produced even when a dominant-negative form
of Chk2 is overexpressed.
VRK1 stabilizes p53 by a posttranslational mechanism. To
determine if p53 accumulation is likely to be posttranslational,
H1299 cells were transfected with pCB6p53 alone or to-
gether with pcDNA-VRK1myc and incubated in the presence
of cycloheximide, which blocks de novo protein synthesis. Cel-
lular extracts were prepared at different times after cyclohex-
imide addition, and the level of p53 protein was determined by
immunoblot analysis. As shown in Fig. 3A, in the presence of
cycloheximide, the overexpression of VRK1 resulted in a re-
duced rate of p53 degradation in the cells. Therefore, VRK1
increases the stability of the protein. The half-life of the trans-
fected p53 protein in this cell line increased from 8 to 13.5 h as
a consequence of VRK1 overexpression.
To exclude any transcriptional effect on the p53 gene, the
FIG. 2. (A) Overexpression of VRK1 increases the steady-state levels of transiently expressed p53. Human H1299 cells (p53 null) were transfected
with 1 g of plasmid encoding wild-type p53 (pCB6p53) either alone or together with 8 g of VRK1 construct (pcDNA-VRK1myc). Cells were also
transfected with pCB6 empty vector or VRK1 alone as controls. Then, p53 was immunoprecipitated, and Thr18 phosphorylation was detected using
the FTP18 monoclonal phosphor-specific antibody. An autophosphorylation kinase assay was performed with Myc-tagged inmmunoprecitated protein to
show that the exogenously expressed kinase was active. IP, immunoprecipitaton; IB, immunoblotting. (B) The introduction of a substitution, K179E, in
the catalytic site of VRK1 generates a kinase that is not active, either on itself (autocatalytic activity) or on other substrates, such as the GST-p53 fusion
protein (FP221). The inactive VRK1 protein (K179E) does not induce accumulation of p53. Zero, 3, 5, and 8 g of the kinase-inactive plasmid were
expressed in combination with p53. , present; , absent. (C) The accumulation of p53 is dependent on the amount of VRK1. H1299 cells were
transfected with a fixed amount of pCB6p53 (1 g) and various amounts of pcDNA-VRK1myc (0, 3, 5, and 8 g). In similar experiments, the cells were
transfected with various amounts of pCDNA-Chk2myc (0, 3, 5, and 8 g) as a control to show its lack of effect on p53 accumulation by itself. (D) In vitro
kinase assay to show that VRK1 does not phosphorylate GST-Chk2-A347 kinase-dead fusion protein (top). 32P, autoradiography; Co, Coomassie
staining. The stabilization of p53 induced by VRK1 in H1299 cells is not affected if the cotransfection is performed in the presence of an active
(pCMV-FLAG-Chk2) or inactive dominant-negative (pCMV-FLAG-Chk2-A347) form of Chk2 protein (bottom). Five micrograms of VRK1 or Chk2
construct was used in combination with 1 g of p53.
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levels of p53 RNA were also determined by quantitative RT-
PCR and agarose gel analysis (Fig. 3B). The levels of p53 RNA
were similar in cell lines transfected with only the p53 plasmid
or a combination of p53 and VRK1 expression plasmids.
Therefore, we concluded that the stabilization effect that
VRK1 exerts over exogenously expressed p53 is likely due to a
posttranslational event of p53.
VRK1 accumulates transcriptionally active p53. Human
H1299 cells (p53/) were cotransfected with the plasmid
pCB6p53 (human p53) and the construct pcDNA-VRK1myc
for human VRK1 expression. The subcellular localization of
both proteins was determined by confocal microscopy. Those
cells that expressed only the p53 expression plasmid showed a
relatively low level of p53 protein, while cells that expressed
both proteins, p53 and VRK1, presented a much higher level
of p53 protein (Fig. 4A). Therefore, VRK1 appeared to pro-
mote the accumulation of p53 protein within the nuclei.
A consequence of the accumulation of p53 would be the
activation of transcription. Therefore, it was decided to test if
the p53 protein stabilized by VRK1 was transcriptionally ac-
tive. For this purpose, H1299 cells were transfected with
pCB6p53 either with or without pcDNA-VRK1myc. Expres-
sion of luciferase activity was determined using three different
reporter plasmids, a construct that has several synthetic p53
response sequences (p53-Luc), and two gene-specific promot-
ers, p21-luc and p14-3-3-luc. As controls, empty vector or
VRK1 alone were also cotransfected, together with the re-
porter construct. The transfection of pCB6p53 alone pro-
moted some transcription due to its overexpression, and the
cotransfection of pcDNA3-VRK1myc with pCB6p53 re-
sulted in a further increase in p53-dependent transcription,
which is higher with the synthetic p53 response elements than
with the gene-specific promoters (Fig. 4B). Therefore, it was
concluded that the p53 molecule stabilized by VRK1 is tran-
scriptionally active, because it activates p53-dependent tran-
scription.
Thr18 phosphorylation interferes with p53 binding to
Mdm2 but does not affect its ubiquitination by Mdm2 in vivo.
Phosphorylation of Thr18 is likely to be one of the components
required for the stabilization of p53 by disruption of the p53-
Mdm2 interaction (20, 43). The Thr18 residue forms a hydro-
gen bond with Asp21 that is essential to maintain the structure
of the -helix in the p53 molecule responsible for the interac-
tion between the two proteins (20, 23, 43). To further charac-
terize the possible effect of VRK1 on this interaction, we de-
termined the phosphorylation of p53 and Mdm2 amino termini
by VRK1. A bacterially expressed GST-VRK1 fusion protein
was able to phosphorylate p53 in Thr18, but not the p53 mu-
tant T18A, in vitro (Fig. 5A). GST-p53 constructs with the
other domains of the p53 molecule did not show a significant
FIG. 3. (A) VRK1 increases the stability of p53 by a posttranslational mechanism. H1299 cells were transfected with p53 with () and without
VRK1. Twenty-four hours after the transfection, cycloheximide (CHX) was added to the cultures and the levels of p53 protein at different time
points were determined by Western blotting. The quantitation of protein levels is shown below the blot. The half-life of p53 increased from 8 to
13.5 h in the presence of VRK1. The straight lines represent the linear regression adjustment of the individual time points. (B) VRK1
overexpression does not affect p53 RNA levels. Real-time quantitative RT-PCR was performed with 100 ng of total RNA obtained from H1299
cells transfected as for Fig. 2A. The amplification curve and a sample of the final product in an agarose gel (inset) are shown.
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phosphorylation in this assay. There was weak detection of p53
(amino acids 290 to 390) fragment phosphorylation compared
with that in Thr18, so we excluded a role for VRK1 in phos-
phorylating this part of the protein in vivo. Furthermore,
VRK1 does not appear to phosphorylate Mdm2 in its p53-
binding region (Fig. 5A) or in the entire Mdm2 protein (data
not shown); thus, any potential effect of VRK1 on the p53-
Mdm2 interaction is likely to be a consequence of the phos-
phorylation on p53.
To study the effect of VRK1 phosphorylation on the p53-
Mdm2 interaction, pull-down experiments were performed us-
ing the GST-p53 fusion protein with residues 1 to 85 (FP221)
in combination with the in vitro-transcribed and -translated
Mdm2 protein that was labeled with [35S]methionine. The
GST-p53 protein binds to Mdm2, but if GST-p53 protein was
previously phosphorylated in vitro with VRK1, the in vitro
binding to Mdm2 was markedly reduced (Fig. 5B). The in vitro
phosphorylation of Thr18 was detected with a specific mono-
clonal antibody (9); the nonphosphorylatable mutant of p53,
p53T18A, did not bind to Mdm2 as expected based on struc-
tural information (23), which confirms the importance of this
residue for the structure of the p53 interaction loop that is
destabilized when the threonine hydroxyl group is lost, either
by phosphorylation or substitution by alanine.
The intracellular level of p53 is regulated by proteolytic
degradation mediated by interaction with Mdm2 that targets
p53 for degradation by the ubiquitin pathway in the protea-
some. Therefore, to test whether VRK1 could affect this reg-
ulatory process in vivo as well, H1299 (p53/) cells were
transfected with pcDNA-VRK1myc with and without p53
(pCB6p53) and with plasmid pCOC-Mdm2 as appropriate.
The cotransfection of p53 together with Mdm2 resulted in a
very significant reduction of p53 levels, an effect opposite that
of VRK1, which increased its levels (Fig. 5C). However, the
cotransfection of pCB6p53 and pCOC-Mdm2 with pcDNA-
VRK1myc partially prevented the Mdm2-induced degradation
of p53, although p53 accumulation did not reach the levels
obtained with VRK1 alone (Fig. 5C). These data could be
explained by two different mechanisms, suggesting that at least
part of the VRK1 effect is mediated by interference with the
Mdm2-induced degradation of p53, presumably through p53
Thr18 phosphorylation, or that VRK1 overexpression induces
FIG. 4. (A) Accumulation and stabilization of nuclear p53 induced by overexpression of VRK1 detected by confocal microscopy. Human H1299
cells (p53/) were transfected with pcDNA3.1-VRK1-myc and pCB6p53. At 36 h postransfection, the cells were analyzed by confocal
microscopy with an anti-Myc (labeled with Cy3) or anti-p53 (labeled with Cy2) antibody. The bars represent 20 m. (B) Activation of
p53-dependent transcriptional activity by VRK1 in H1299 cells. Cells were cotransfected with p53 with or without VRK1 and a p53 synthetic
reporter plasmid or specific gene promoters, p21-Luc and the 14-3-3-Luc, containing p53 response elements. Reporter luciferase activity was
normalized for transfection levels with Renilla luciferase. The error bars represent standard deviations.
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FIG. 5. (A) Phosphorylation of p53 in Thr18 in vitro by using GST-VRK1 fusion. As substrates in the kinase reaction, GST-p53wt (FP221 fusion
protein), GST-p53T18A (amino acids 1 to 85), GST-p53 (amino acids 90 to 290), GST-p53 (amino acids 290 to 390), GST-Mdm2 (amino acids
1 to 188), and GST proteins were used together with 2 g of GST-VRK1 in a radioactive kinase assay. At the bottom is shown staining of the gel
with Coomassie blue. ns, nonspecific band. (B) Effect of p53 phosphorylation in Thr18 interferes with its binding to Mdm2 analyzed in a pull-down
assay. The wild-type GST-p53 and its phosphorylated form with VRK1 were mixed with Mdm2 protein that was synthesized and labeled in an in
vitro transcription-translation system with [35S]methionine. The bound Mdm2 was detected by its radioactive signal, which was used for quanti-
tation as represented by the bars. The GST-p53 protein loaded in the gel was detected by Coomassie blue staining. Thr18 phosphorylation was
detected with the FTP18 monoclonal antibody. (C) H1299 human tumor cells (p53/) cotransfected with VRK1 show stabilization of p53, which
is partially reverted but not abolished by overexpression of cotransfected Mdm2. H1299 cells were transfected with 1 g of pCB6p53 expression
plasmid alone or together with plasmids pCOC-Mdm2 (2 g) and pCDNA-VRK1 (4 g) where indicated. One microgram of plasmid encoding
ubiquitin was added in all cases. Whole-cell extracts were prepared 36 h after transfection and analyzed by Western blotting with the corresponding
antibody. (D) The stabilization of p53 by VRK1 is to some extent independent of the presence of Mdm2. Mouse embryo fibroblasts derived from
double-knockout mice (p53/ Mdm2/) were cotransfected with the indicated proteins. The cells were processed as for panel C. MG132
proteasome inhibitor was added for 6 h prior to lysis where indicated on the right. (E) Effect of VRK1 on the ubiquitination of p53 by Mdm2.
H1299 cells were transfected with the indicated proteins as for panel C, and 25 M proteasome inhibitor MG132 was added 30 h after transfection
for 6 h. Total p53 was immunoprecipitated with the polyclonal antibody CM1 and detected with the monoclonal antibodies DO-1 and Pab1801.
Mdm2 protein coimmunoprecipitated and was detected using the 4B2 antibody. The ubiquitinated form of p53 is indicated. IP, immunoprecipi-
tation; IB, immunoblotting.
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p53 accumulation independently of the Mdm2 effect. There-
fore, to elucidate the real involvement of p53-Mdm2 interac-
tion in this process, similar cotransfection experiments were
carried out using a murine fibroblast cell line derived from a
double-knockout mouse for p53 and Mdm2. In these cells, the
cotransfection of p53 together with VRK1 also resulted in an
increase in the intracellular levels of p53 (Fig. 5D). Interest-
ingly, VRK1 was not able to increase the stabilization of p53
induced by the blocking of the proteasome-directed degrada-
tion with the inhibitor MG132 in the absence of Mdm2, indi-
cating that VRK1 in this system also increased the stability of
p53 protein by interfering with its degradation and not by any
other mechanism (Fig. 5D). This result indicates that the
VRK1 effect on p53 stabilization is at least partially mediated
by an Mdm2-independent process despite the lack of expres-
sion of Mdm2 protein in this cell line but is produced in the
absence of Mdm2 by interfering with the degradation of p53 in
any other way. VRK1 does not appear to significantly affect the
p53 ubiquitination directed by Mdm2, although a slight reduc-
tion in the amount of Mdm2 bound to p53 in the presence of
VRK1 overexpression was detected (Fig. 5E). Therefore, the
effect of VRK1 on p53 is not mainly mediated by disruption of
the p53-Mdm2 interaction, although this might be an indirect
consequence of p53 threonine-18 phosphorylation by VRK1,
which contributes to p53 stabilization under some circum-
stances. p53 is not only targeted for degradation in the pro-
teasome by Mdm2, since a role for other ubiquitin ligases, such
as COP1 or Pirh2, has been established (14, 24), although the
mechanism of regulation of p53 activity by these other proteins
is not so well understood. VRK1 might still affect p53 degra-
dation by interaction with these or other p53 negative regula-
tors.
Effect of VRK1 can cooperate with p300 and MdmX in p53
stabilization. Other molecules that interact with the p53 N
terminus, such as the transcriptional coactivator p300 that
acetylates p53 (53), and the MdmX protein (29, 47) can also
contribute to p53 stabilization. The recruitment of p300 pro-
tein to Thr18 and Ser20 phosphorylation and the subsequent
p53 acetylation and stabilization have been described (11).
MdmX overexpression stabilizes and activates p53, leading to
accumulation of nuclear p53, without affecting its Mdm2-me-
diated ubiquitination (47). Therefore, we decided to test
whether the effect exerted by VRK1 on p53 was mediated by
p300 or MdmX in our system. H1299 cells were transfected
with p53 and the combination of VRK1, or Chk2 as a control,
with p300. The total p53 molecule was immunoprecipitated
from the transfected cells, and the blot was developed with an
antibody recognizing specifically acetylated Lys373 and Lys382
in p53, an indicator of p300 activity (Fig. 6A). VRK1 by itself
slightly increases the acetylation of p53, presumably by endog-
enous p300, but at a level lower than when exogenous p300 is
expressed. When both proteins are cotransfected together with
p53, an increase in p53 acetylation could be seen compared
with that obtained by p300 overexpression alone. As a control,
this effect is not exerted by Chk2 (Fig. 6A). To confirm that
VRK1 might contribute to increased p53 binding to p300, total
p300 was immunoprecipitated and the amount of p53 bound
was detected with a specific antibody. A slight increase in p53
binding to p300 could be detected upon VRK1 overexpression,
indicating an increase in the formation of the p53-p300 com-
plex (Fig. 6B).
Next, the effect of MdmX was determined. Both VRK1 and
MdmX overexpression by themselves stabilize p53, and when
both are cotransfected in H1299 cells, the level of p53 is even
higher (Fig. 6C). These data might suggest that MdmX- and
VRK1-directed p53 stabilization processes can function inde-
pendently, although they could cooperate in the cell to reach
complete p53 stabilization and might interact in an unknown
manner. These data indicate that the effect on p53 stabilization
induced by VRK1 might be to promote p53 interactions with
stabilizing proteins, such as p300 or MdmX.
To show whether p53 Thr18 phosphorylation was the unique
event necessary for VRK1-induced p53 stabilization, we per-
formed a cotransfection experiment using the single-point mu-
tation to alanine of p53 in this phosphorylatable residue.
VRK1 overexpression was able to induce an increase in p53
levels even in the absence of possibility of phosphorylation,
suggesting the existence of another mechanism distinct from
direct p53 phosphorylation that could involve interactions with
p53 activators, such as p300. Nevertheless, threonine-to-ala-
nine substitution in position 18 is thought to mimic the phos-
phorylation at this residue regarding the interaction of the p53
amino terminus with other proteins, as it disrupts the necessary
hydrogen bond in the p53 molecule (20, 43). In fact, an in-
crease in the transactivation activity of this mutant has been
reported, affecting p53-mdm2 interaction but without affecting
or even promoting p53 interaction with transcriptional coacti-
vators, such as TAFII31 (20). The apparent absence of intrinsic
p53T18A protein stability indicates the presence of other p53
degradation processes, such as the participation of other p53
ubiquitin ligases. All this makes interpretation of the results
with this modified protein difficult. Furthermore, the block of
p53 degradation by specific proteasome inhibitors causes a
p53T18A accumulation that is not further increased by VRK1
overexpression (Fig. 6D), indicating that the effect of VRK1 on
p53T18A is possibly still related to the inhibition of its degra-
dation, although probably not by Mdm2.
VRK1 overexpression increases endogenous p53 Thr18
phosphorylation and acetylation. We overexpressed VRK1 in
the lung carcinoma cell line A549, which expresses wild-type
p53 at significantly high levels, to study the effect of VRK1 on
the endogenously expressed p53 (Fig. 7A, left). We were not
able to see an accumulation of p53 at the levels obtained for
the exogenously expressed protein. Probably, the endogenous
p53 status did not make it possible to detect the effect of
VRK1-induced accumulation observed with the transfected
protein, which is expressed de novo and at levels that resemble
an initial stress and localized directly in the nucleus without the
requirement for any shuttle from the cytoplasm. It was possible
that this status would be necessary for the VRK1 effect on p53
or that the high levels of p53 in this cell line made it difficult to
measure this activation by Western blotting in an overall pop-
ulation where every cell expresses p53 but not the transfected
VRK1. We decided to analyze the p53 phosphorylation status
under these conditions, and we observed that there was an
increase in p53 phosphorylation at Thr18 greater than the one
observed upon transfection itself, as Lipofectamine elicits a
“stress-like” response in human cells (38). This phosphoryla-
tion reached a level similar to that induced by treatment of
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these cells with adriamycin, a DNA damage-inducing agent
that increases p53 Thr18 phosphorylation (38). We have dem-
onstrated that this DNA-damaging agent does not produce any
effect on VRK1 expression or activity (data not shown). An
increase in the p53 acetylated form was also measured after
VRK1 overexpression (Fig. 7A, right). A smaller increase in
phosphorylation could also be seen in Ser15, suggesting the
idea of collaboration of VRK1 with other kinases, as VRK1
does not phosphorylate the Ser15 residue by itself. This in-
crease in Thr18 phosphorylation is not sufficient to accumulate
p53 at levels detectable by Western blotting, but it has been
reported that this phosphorylation increases p53 transcrip-
tional activity (15, 20). To detect in an indirect way the ex-
pected accumulation of p53 induced by VRK1, we measured
p53-dependent transcription in the A549 cell line using the Bax
gene promoter with luciferase as a reporter system containing
a p53 response element (Fig. 7B). We observed an increase in
p53-dependent transcription in these cells upon VRK1 over-
expression even without a detectable increase in p53 protein
levels. Therefore, we concluded that VRK1 overexpression in
the A549 cell line activates p53-dependent transcription and
increases endogenous p53 amino-terminal phosphorylation.
Similar results were obtained with other p53 wild-type cancer
cell lines.
VRK1 protein expression suppression by specific siRNA
provokes defects in cell proliferation. VRK1 does not seem to
FIG. 6. (A) H1299 cells were transfected with pCB6p53, pCDNA-VRK1-myc, pCMV-p300-HA, or pCMV-Chk2 as indicated. The trans-
fected p53 was immunoprecipitated using monoclonal antibodies, and the blot was analyzed for the acetylation of p53 on Lys 373 and Lys382 with
a specific antibody. IP, immunoprecipitation; IB, immunoblotting. (B) VRK1 promotes the formation of a p53-p300 complex. H1299 cells were
transfected with different combinations of the indicated plasmids (pCMV-p300-HA, pCB6p53, and pCDNA-VRK1-myc). Extracts from trans-
fected cells were immunoprecipitated with an anti-p300 polyclonal antibody, and the blot was developed with either anti-HA to detect immuno-
precipitated transfected p300 or anti-p53 to detect the coimmunoprecipitated p53. (C) H1299 cells were transfected with pCB6p53, pVRK1-HA,
and p3.1MdmX-myc as indicated, and the levels of p53 were determined with a mix of anti-p53 antibodies. Quantification of the amount of p53
is shown below. (D) The H1299 cell line was transfected with plasmid encoding p53 with a substitution of Thr18 for alanine (1 g) with or without
pCDNA-VRK1-myc (8 g), and 36 h postransfection, whole-cell extract was subjected to immunoblotting to detect p53 total protein. Six hours
prior to extract collection, MG132 was added to the cells where indicated.
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be activated by DNA damage or any other classical p53-acti-
vating stress. All the previous data point to an involvement of
VRK1 in cell growth and proliferation regulation (34, 49).
Suppression of VRK1 homologous expression by siRNA in C.
elegans has a phenotype consistent with this role (22). We
proposed that VRK1 might have a role in p53 initial activation
during normal cell proliferation rather than during severe
stress, and to test whether in fact VRK1 plays a role in this
property, we decided to perform transient siRNA transfection
targeting VRK1 expression. We used the HCT116 cell line,
with wild-type p53, a high proliferation rate, and easy trans-
fection of siRNA duplexes, for these experiments. We tested
four different siRNA duplexes by Western blotting and immu-
nofluorescence assays, first as a pool and then as individual
duplexes, for the ability to specifically suppress VRK1 expres-
sion in these cells (Fig. 8A). A reduction to 	20% of the initial
amount of VRK1 protein was obtained. All the experiments
were finally carried out with two independent duplexes
(siVRK1-1 and -2). Cells were analyzed by video microscopy
36 to 80 h after transfection (Fig. 8B). Cells transfected with
the control nontargeting siRNA divided normally and reached
near confluence on the plate after 80 h. The cells completed
their divisions in 1.5 to 2 h on average, the same time as
nontransfected control cells. However, cells transfected with
the specific siVRK1 failed to divide normally and as a conse-
quence did not reach 50% confluence at the same time. The
average time spent in cell division was abnormal. Some cells
completed cell division normally, while others remained de-
tached from the plate surface for 7 to 10 h before cytokinesis
and attachment of the daughter cells to the plate occurred.
Almost 50% of the cells analyzed collapsed before completion
of cell division and died, or they divided and at least one of the
daughter cells died. We also quantified cell proliferation in an
indirect form by measuring metabolically active cells, using the
XTT reagent, 60 h after transfection with siRNA (Fig. 8C). A
decrease in cell proliferation after VRK1 suppression was de-
tected.
DISCUSSION
In this report, it was shown that a novel kinase, VRK1, a
member of a new Ser-Thr kinase family, is able to contribute to
the stability and nuclear accumulation of a transcriptionally
active p53 molecule. This accumulation is clearly due to a
posttranslational effect on p53. Due to the activity of the
VRK1 protein and the change in the phosphorylation status of
p53 after its stabilization, this effect was likely to be a conse-
quence of the kinase activity of VRK1. Recently, it has been
shown that p53 stabilization can occur in the absence of Ser15
or Ser20 phosphorylation (2, 21a), suggesting that other resi-
dues, such as Thr18, might play a more prominent role under
these circumstances. Phosphorylation of p53 in Thr18 by
VRK1 abolishes the interaction between it and Mdm2 in vitro
and can partially prevent the downregulation of p53 by Mdm2.
However, VRK1 has no significant effect on Mdm2-dependent
p53 ubiquitination, although it could impair the formation of
the complex, as seen in coimmunoprecipitation experiments.
Moreover, the cumulative effect induced by VRK1 is also de-
tected in cells with no expression of Mdm2, as in murine
p53-Mdm2 double-null cells. This observation indicates that,
although the interruption of the p53-Mdm2 interaction might
play a role in promoting p53 transcriptional activity, VRK1 can
also stabilize p53 by an alternative mechanism different from
its effect on the interaction with Mdm2. This mechanism might
also be related to inhibition of the degradation of p53, since it
does not have an additive effect with the stabilization induced
by the proteasome-specific inhibitor MG132 (Fig. 5D).
MdmX has been shown to inhibit p53 transactivation activity
and to stabilize p53 by an antagonist effect of Mdm2-depen-
dent degradation. The latter effect is exerted without affecting
the p53 ubiquitination pattern (47). MdmX overexpression
leads to p53 stabilization, and the view of this protein as a
positive regulator of p53 under stress conditions is gaining
relevance (29). In H1299, overexpression of MdmX stabilized
the exogenously expressed p53 similarly to VRK1. Further-
more, the overexpression of both VRK1 and MdmX at the
same time induces a greater increase in p53 levels (Fig. 6C).
This could mean that VRK1 does not act on p53 by the same
FIG. 7. (A) VRK1 induces endogenous p53 phosphorylation and
acetylation. A549 cells were transfected either with 4 g of pCEFL-KZ
plasmid alone or with HA-VRK1 construct and subjected to Western
blotting with specific antibodies to detect p53 phosphorylated in Thr18,
Ser15, or total protein. Untransfected cells and adriamycin (ADR)-
treated cells are shown as controls (left). Total p53 protein was then
immunoprecipitated (IP) and subjected to Western blotting to detect
the acetylated form of the protein (right). (B) VRK1 overexpression
enhances p53-dependent transcription. Cells were cotransfected with
HA-VRK1 and a Bax reporter plasmid containing p53 response ele-
ments. Reporter luciferase activity was normalized for transfection
levels with Renilla luciferase. The error bars represent standard devi-
ations.
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mechanism as MdmX, since their effects are additive, although
we cannot exclude collaborative effects on p53 activation. Fur-
ther studies are needed to clarify this point.
Another candidate for VRK1 action is the p300 coactivator.
It has been reported that p300 binding to the amino-terminal
domain of p53 is regulated by phosphorylation in residues such
as Ser20 and Thr18 that promotes its union and impairs the
Mdm2 interaction in the same region (11, 12, 13). We show in
this report that VRK1-induced stabilized p53 is extensively
phosphorylated in Thr18, as is endogenous p53 upon VRK1
overexpression. As we describe, VRK1 overexpression induces
p53 acetylation in residues Lys373 and Lys382 (Fig. 6A), typ-
ically acetylated by p300, and enhances the formation of stable
p53-p300 complexes (Fig. 6B). These data suggest a mecha-
nism by which VRK1 can stabilize and induce p53 transcrip-
tional activity. However, VRK1 is able to induce the accumu-
lation of the nonphosphorylatable p53 mutant T18A, a mutant
that has been shown to have some of the properties of the
phosphorylated protein. This observation leaves the door open
to another possible mechanism, in addition to the direct phos-
phorylation of p53. This mechanism might involve phosphor-
ylation or interaction with other activators of p53, such as p300,
linking the two effects. Phosphorylation might favor the bind-
ing of p53 to other stabilizing molecules, perhaps by a docking
mechanism in which VRK1-p53 transient interaction might
favor the activation of p53 by promoting binding to other
effectors, with p53 phosphorylation by VRK1 being an indis-
pensable mechanism (8). VRK1 could also affect the action of
other p53 ubiquitin ligases, such as COP1 and Pirh2 (14, 24), or
another that has not yet been found, leading to p53 stabiliza-
FIG. 8. VRK1 suppression by specific siRNA provokes abnormalities in proliferation. (A) HCT116 cells were transfected with the specific
siRNA for VRK1 (siVRK1), nontargeting siRNA (siCONTROL), or lamin-targeting siRNA (siLamin). Then the cells were processed for Western
blotting or immunofluorescence assay as previously described with a specific antibody against endogenous VRK1 (red) or nuclear staining (DAPI).
NTC, nontransfected cell control; TC, transfected cell control without siRNA. (B) After transfection as for panel A, cells were submitted to in vivo
video microscopy. Representative images of cells 36 and 80 h after transfection are shown. The durations of cell division (plus standard deviations)
were determined for 20 to 40 cells from several different experiments (below). (C) Quantification of cell proliferation and viability determined 60 h
after transfection by colorimetric XTT-based assay.
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tion by interfering with proteasome-dependent p53 degrada-
tion. These proteins exert their effects independently of Mdm2
and bind to p53 in a different region, explaining why VRK1 is
still capable of stabilizing p53 in the absence of Mdm2 or with
the T18A mutation. The abolition of the effect of VRK1 on
MG132-stabilized p53 even in the absence of Mdm2 might
indicate that VRK1 is still acting by disruption of p53 degra-
dation. VRK1 activation of p53 might also involve a coopera-
tive effect with other kinases. Indeed, an increase in Ser15
phosphorylation can be observed after VRK1 overexpression
(Fig. 7A). Nevertheless, the effect of VRK1 on p53 could still
be seen in the presence of ATM kinase inhibitors (unpublished
data), such as caffeine or wortmannin (42), indicating that
prior phosphorylation of these residues by this kinase is not
necessary. This alternative mechanism remains to be eluci-
dated and is under investigation.
The phosphorylation of p53 is probably conditioned by the
particular set of kinases activated in response to a specific
stimulus. Thr18 phosphorylation is a component of the cell
response to genotoxic damage, in which a complex web of
signaling pathways converge in several p53 residues, such as
Ser15, Thr18, and Ser20 (38). Thr18 phosphorylation has been
reported to be carried out specifically by Chk2 (8), although
the role of this kinase in the p53 pathway is controversial (1,
51), and by CK1, with the prior phosphorylation of Ser 15 (16,
39). A docking mechanism between p53 and Chk2 has been
proposed that leads to p53 phosphorylation in Thr18 and Ser20
by this kinase (8). VRK1 phosphorylation of p53 is indepen-
dent of the Chk2 role, as can be seen, for example, when a
dominant-negative form of the protein is expressed together
with VRK1 (Fig. 2C and 6A).
The consequence of the p53 accumulation induced by VRK1
is the activation of transcription of p53-dependent promoters,
such as a synthetic p53 response element, or some specific
promoters, such as the p21 promoter. This observation is con-
sistent with the parallel accumulation of p21 protein when
there is phosphorylation of Thr18 in response to irradiation
and with the promotion of binding to general transcription
factors, such as TAFII31 (20).
Nothing is known about the regulation and stimulation of
FIG. 9. Diagram illustrating proposed VRK1 action on p53. Two types of cycles can regulate p53 functions. One of the cycles is operational
under normal proliferation conditions (blue box), where the damage is occasional and minimal and not enough to trigger a full p53 stress response.
VRK1 somehow regulates proliferation and might be involved in p53 basal stabilization during normal proliferation. In response to severe or
catastrophic damage (red box), like that induced by radiation, chemotherapy, or severe failure of DNA replication, p53 is fully activated and
triggers a complete p53 response. Well-known kinases, such as ATM and ATR, are implicated in this p53 activation.
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VRK1 activity. VRK1 activity by itself is not affected by geno-
toxic treatment with adriamycin, etoposide, or hydroxyurea,
thus excluding response to these stresses as the physiological
connection between VRK1 and p53. VRK1 is ubiquitously
expressed, and its expression is high in all cell types tested. The
highest levels are detected in proliferating cells, such as the
expansion of the murine hematopoietic system (49), prolifer-
ating tumor cell lines (34), or the proliferation compartment in
tumor biopsies (unpublished). The data obtained from the
homologous C. elegans protein also point to a role in the
regulation of cell proliferation (22). Using specific siRNA ex-
periments to transiently suppress VRK1 protein expression, we
have shown that human VRK1 is also important for normal
proliferation. Cells without VRK1 have different defects in
proliferation, being unable to complete normal cell division
and inducing cell death in some cases (Fig. 8). The exact
mechanism of this effect needs to be further characterized. We
propose a model for VRK1 action on p53 (Fig. 9). Under
physiological nonstress conditions, the VRK1-p53 connection
might function as a basic mechanism that maintains a basal
level of p53 protein in a ready status. VRK1 might induce an
initial activation of p53 that is not sufficient to trigger a full p53
response but is enough to respond to minor and suboptimal
damage, such as an occasional individual replication block,
during normal proliferation, and it possibly induces the full
activation of p53 in case of severe damage during cell division
(Fig. 9). This minor activation of p53 by VRK1 could help
maintain a basal level of expression of p53. When severe or
catastrophic damage occurs, such as exposure to irradiation or
chemotherapeutic drugs, additional mechanisms that promote
additional effects in addition to repair, such as growth arrest or
apoptosis, become active (Fig. 9). These secondary mecha-
nisms are very well characterized and implicate well-known
kinases, as the ATM-Chk2 or ATR-Chk1 route.
We conclude that VRK1 represents a new regulator of cell
proliferation and could also be the first step in a new pathway
regulating p53 in normal proliferating cells that might function
as a switch controlling the proteins that interact with p53 and
thus modify its stability and activity.
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